Galderma: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis

 

• Latest data from the phase III OLYMPIA 2 trial presented at the World Congress of Dermatology (WCD) showcase rapid onset of action of nemolizumab in adult patients with prurigo nodularis, with 19.7% of patients treated with nemolizumab monotherapy achieving an itch-free state as early as week 4 after only one dose of nemolizumab¹
• 100% of adults with prurigo nodularis have reported intense itching caused by the condition as their top complaint²
• Nemolizumab is a first-in-class investigational monoclonal antibody that blocks the signaling of IL-31, widely recognized as the itch cytokine and a central mediator of inflammation and fibrosis in prurigo nodularis

https://www.biospace.com/article/releases/galderma-wcd-2023-late-breaking-phase-iii-results-for-nemolizumab-monotherapy-in-prurigo-nodularis-show-a-significant-proportion-of-itch-free-patients-by-week-4/